ArticleEuropean journal of clinical pharmacology2021
An open-label, positron emission tomography study of the striatal D
Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00805454 (A Phase I, Open-Label,Positron Emission Tomography), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Do Brain Extracellular Fluid Concentrations Predict PET-Inferred Receptor Occupancy in Human CNS? A Mechanistic Model-Based Analysis of Dopamine D2 Receptor Ligands.Clinical pharmacology and therapeutics · 2026Article
- The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis.BMC psychiatry · 2025Article
- Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.Neuropsychiatric disease and treatment · 2025Article
- PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Brexpiprazole-Pharmacologic Properties and Use in Schizophrenia and Mood Disorders.Brain sciences · 2023Review
- Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study.Frontiers in psychiatry · 2023Article
- Perceptual inference, accuracy, and precision in temporal reproduction in schizophrenia.Schizophrenia research. Cognition · 2022Article
- PET as a Translational Tool in Drug Development for Neuroscience Compounds.Clinical pharmacology and therapeutics · 2022Review
- Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice.Frontiers in psychiatry · 2022Review
- Effect of Novel Antipsychotics on Energy Metabolism - In Vitro Study in Pig Brain Mitochondria.Molecular neurobiology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeThe aim of this Phase 1, open-label, positron emission tomography (PET) study was to determine the degree of striatal D
methodsOccupancy was measured at 4 and 23.5 h post-dose using the D
resultsFifteen healthy participants were enrolled (mean age 33.9 years; 93.3% male). Mean D
conclusionBy extrapolating the observed single-dose D
trial registrationClinicalTrials.gov NCT00805454 December 9, 2008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.